EUVIMEDEUVIMED entdecken
Crossref

The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma

Yoshiro Ito, Daisaku Yamada, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Yoshito Tomimaru, Tadafumi Asaoka, Takehiro Noda, Hidenori Takahashi, Junzo Shimizu, Yuichiro Doki, Hidetoshi Eguchi

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.216997 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Yoshiro Ito und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2(E2), Suita, Osaka, 565-0871, Japan. Electroni…. Hauptthemen laut MEDLINE: Gemcitabine, Cholangiocarcinoma, Deoxycytidine, Drug Synergism. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-FGFR treatment for cholangiocarcinoma (CCA) with fibroblast growth factor receptor (FGFR) alteration is a promising treatment option. Since the antitumor mechanisms of anti-FGFR inhibitors and conventional cytotoxic drugs differ, synergistic effects can be possible. This study aimed to evaluate the efficacy of the combined administration of gemcitabine (GEM) and pemigatinib in CCA cells with FGFR2 alterations. To simulate the treatment for patients with 3 kinds of CCA, chemonaïve CCA with activation of the FGF pathway, chemo-resistant CCA with activation of the FGF pathway, and CCA without FGF pathway activation (as controls), we evaluated 3 different CCA cell lines, CCLP-1 (with a FGFR2 fusion mutation), CCLP-GR (GEM-resistant cells established from CCLP-1), and HuCCT1 (without FGFR mutations). There was no significant difference between CCLP-1 and HuCCT1 in GEM suspensibility (IC50 = 19.3, 22.6 mg/dl, p = 0.1187), and the drug sensitivity to pemigatinib did not differ between CCLP-1 and CCLP-GR (IC50 = 7.18,7.60 nM, p = 0.3089). Interestingly, only CCLP-1 showed a synergistic effect with combination therapy consisting of GEM plus pemigatinib in vitro and in vivo. In a comparison of the reaction to GEM exposure, only CCLP-1 cells showed an increase in the activation of downstream proteins in the FGF pathway, especially FRS2 and ERK. In association with this reaction, cell cycle and mitosis were increased with GEM exposure in CCLP-1, but HuCCT1/CCLP-GR did not show this reaction. Our results suggested that combination therapy with GEM plus pemigatinib is a promising treatment for chemonaïve patients with CCA with activation of the FGF pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineCholangiocarcinomaDeoxycytidineDrug SynergismBile Duct NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsXenograft Model Antitumor AssaysPyrimidinesReceptor, Fibroblast Growth Factor, Type 2HumansAnimalsCell Line, TumorMiceCell ProliferationMice, NudeSignal TransductionFibroblast Growth FactorsReceptors, Fibroblast Growth FactorDrug Resistance, NeoplasmProtein Kinase InhibitorsMutationApoptosisMorpholinesPyrroles

Stichwörter der Autor:innen

Combination therapyFGFR2 fusion alterationPemigatinibSynergistic effect

Substanzen

GemcitabineDeoxycytidinePyrimidinespemigatinibReceptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanFibroblast Growth FactorsReceptors, Fibroblast Growth FactorProtein Kinase InhibitorsMorpholines

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2(E2), Suita, Osaka, 565-0871, Japan. Electronic address: yito@gesurg.med.osaka-u.ac.jp.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2(E2), Suita, Osaka, 565-0871, Japan.
  • Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2(E2), Suita, Osaka, 565-0871, Japan. Electronic address: skobayashi@gesurg.med.osaka-u.ac.jp.
  • Department of Surgery, Osaka Police Hospital, 10-31 Kitayama-cho Tennoji-Ku, Osaka, 543-0035, Japan.
  • Department of Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka, Osaka, 560-8565, Japan.

Zitieren

APA

Ito, Y., Yamada, D., Kobayashi, S., Sasaki, K., Iwagami, Y., Tomimaru, Y., Asaoka, T., Noda, T., Takahashi, H., Shimizu, J., Doki, Y., & Eguchi, H. (2024). The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216997

Vancouver

Ito Y, Yamada D, Kobayashi S, Sasaki K, Iwagami Y, Tomimaru Y, et al. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216997

BibTeX
@article{Ito2024,
  author = {Ito, Yoshiro and Yamada, Daisaku and Kobayashi, Shogo and Sasaki, Kazuki and Iwagami, Yoshifumi and Tomimaru, Yoshito and Asaoka, Tadafumi and Noda, Takehiro and Takahashi, Hidenori and Shimizu, Junzo and Doki, Yuichiro and Eguchi, Hidetoshi},
  title = {The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.216997}
}
Kostenlos starten →